Background: A subgroup of anaplastic lymphoma kinase (ALK)-rearranged lung tumours can respond to ALK inhibitors. Until now, the ALK status in circulating tumour cells (CTCs) isolated from patients with lung cancer has not been characterised. We assessed the ALK status in CTCs detected in patients with lung cancer and correlated the results to the ALK status defined in the corresponding tumour tissue.
Introduction
Lung cancer is the most prevalent neoplasm and the major cause of tumour-related mortality worldwide [1] [2] [3] [4] [5] . Despite the recent advances in the management of resected lung cancers and the more effective treatment of metastatic tumours, the cure rate of patients with lung cancer remains low. However, the recent discovery of driver oncogenic mutations in lung carcinomas and the increasing development of targeted therapies show new encouraging results in advanced stage patients [6] [7] [8] . Among these therapies, gefibinib and erlotinib, tyrosine-kinase inhibitors raised against the epidermal growth factor receptor (EGFR), which exhibit an activating tyrosine mutation in 10%-20% of adenocarcinomas, are used [7, 9] . More Recently, genomic alteration involving the anaplastic lymphoma kinase (ALK) (2p23) and the echinoderm microtubule-associated protein like-4 (EML4) (2p21) genes was identified in a subset of patients with lung cancer having an outstanding favourable response to an ALK small-molecule inhibitor (crizotinib) [7, [10] [11] [12] [13] . The ALK-gene rearrangement was found in 1%-7% of non-small-cell lung cancers (NSCLCs) according to most of the series without KRAS-and EGFR-associated mutations in most of the tumours [10, [12] [13] [14] . Specific histological features characterise this subset of ALK-positive lung adenocarcinomas, presenting with a solid or acinar growth pattern, a cribriform structure, the presence of mucous cells (signet-ring cells or goblet cells), abundant extracellular mucus, a lack of lepidic growth and a lack of significant nuclear pleomorphism [14] . Moreover, patients with tumours with ALK rearrangement were younger, were more frequently males, in most of the series, and were never smokers/former light smokers [12, 14] .
Circulating tumour cells (CTCs) can be isolated in more than 40% of patients with lung cancer according to the series and methods [15] [16] [17] . Moreover, the prognosis of patients with lung cancer, both in late and early stages of the disease, correlates to the presence and the number of CTCs [15, 16] . CTCs can be isolated by different direct and indirect methods [18, 19] . Genomic alterations, particularly mutations occurring in the EGFR gene, have been demonstrated in CTCs isolated in NSCLC patients [20] .
We recently demonstrated that CTCs can be isolated by different methods even in early-stage disease in patients undergoing surgery for lung carcinomas [15, 21] . Moreover, the presence and the number of CTCs were associated with worse prognosis [15] . Interestingly, using a direct method that isolated the CTCs according to their size (isolation by size of epithelial tumour cells, ISET), we defined cytopathological criteria of malignancy, which allowed good characterisation of CTCs with malignant features [22, 23] . In addition, by applying an immunocytochemistry (ICC) approach to CTCs isolated by ISET from NSCLC patients, our group and another group showed that a variable number of CTCs display a epithelio-mesenchymal transition (EMT) phenotype [17, 21, 24, 25] .
The assessment of ALK-gene rearrangement in CTCs isolated from patients with lung cancer has not been reported earlier. However, this may be a relevant clinical goal for noninvasive pre-screening of patients with lung cancer in avoiding potential morbidity related to the lung biopsy and the removal of tumour tissue. The aim of this work was (i) to assess the ALK status in CTCs having cytopathological criteria of malignancy isolated by ISET in 87 patients with lung adenocarcinomas and (ii) to compare the ALK status found in CTCs and in the corresponding tumour tissue. For this purpose, we used an assay based on a dual immunochemical and fluorescence in situ hybridisation (FISH) approach for ALK-gene rearrangement and applied it to both the CTCs and the corresponding tumour tissue samples.
methods patients and samples
In a previous study using the ISET method for patients undergoing surgery for NSCLC, we detected CTCs having cytomorphological malignant features in 76 (37%) of 208 cases [15] . For the present work, we selected from this latter population 40 cases with a primary adenocarcinoma. In addition, 47 patients with lung adenocarcinoma included in the study between May 2011 and December 2011 had CTCs with malignant features. Among these 87 patients, 34 had blood samples (10 ml) collected and treated by ISET at different times: before surgery and at 7 and 15 days after surgery. All patients gave their informed consent to participate in this study. The main clinicopathological features of the selected 87 patients are summarised in Table 1 . Tumours were classified according to the seventh pTNM classification and to the last histological classification of lung adenocarcinomas [26, 27] . FISH analysis was performed on the tumour samples using a break-apart probe for the ALK gene (Vysis LSI ALK Dual Color, Abbott Molecular, Abbott Park, IL; see Supplementary data, available at Annals of Oncology online). To be adequately interpreted, tumour cell nuclei should have at least one co-localisation signal. To be considered as ALK rearranged, at least 15% of interpretable tumour cell nuclei should harbour an abnormal probe hybridisation pattern [28] . Immunohistochemistry (IHC) was performed on deparaffinised sections using a primary antibody against the ALK protein (1:50, 5A4; Abcam, Cambridge, UK) incubated for 45 min at room temperature (Supplementary data, available at Annals of Oncology online). Targeted mutation analysis for (i) EGFR mutation hot spots, (ii) KRAS mutation hot spots and (iii) BRAF mutations was carried out from DNA extracted from frozen tumour tissue sections by pyrosequencing, as previously described [29, 30] (Supplementary data, available at Annals of Oncology online). 
ICC and FISH on ISET filters
ICC and FISH were performed on CTCs isolated using the ISET method on unstained spots of the corresponding filters containing CTCs with malignant features detected by MGG staining on six spots [15] . Two spots were used for ICC and two spots were used for FISH per filter. For ICC, the spots were incubated with a primary antibody against the ALK protein (1:50, 5A4; Abcam, Cambridge, UK) for 30 min at room temperature. The reactions were visualised with 3,3 0 -diaminobenzidine, followed by counterstaining with haematoxylin. Cytoplasmic staining was considered positive for ALK [30] (Supplementary Data). FISH carried out on two or more spots used a break-apart probe for the ALK gene (Vysis LSI ALK Dual Color, Abbott Molecular) in accordance with the manufacturer's instructions. Cells showing split signals or alone 3 0 signals were considered positive for ALK rearrangement [31] . Filters were examined independently and blinded to clinical, IHC, ICC data and tissue genotype. We tested the reproducibility of the ICC and FISH results for ALK detection on CTCs of 102 filters of 34 patients who underwent blood sampling before surgery and 7 and 15 days after surgery. A total of 14-500 interpretable tumour cell nuclei were analysed for each patient. To be correctly interpreted, tumour cell nuclei should have at least one colocalisation signal. To be considered as ALK rearranged, at least 15% of interpretable tumour cell nuclei should harbour an abnormal probes hybridisation pattern.
We used the human NSCLC cell line H2228 obtained from ATCC (Manassas, VA) as an ALK rearrangement positive control [32] . Cells were cultured and maintained in RPMI-1640 medium supplemented with 10% foetal bovine serum, as previously described [32] . Around 50 cells were mixed into 10 ml of a blood sample taken from healthy volunteers. Samples were then filtered using the ISET method, as described previously [23] . FISH using a break-apart probe and ICC with anti-ALK antibodies were then carried out as described earlier.
results
Positive ALK immunostaining was found in five tumours corresponding to adenocarcinomas with a solid predominant structure with mucin production. These five cases showed strong positive cytoplasmic staining (score 3+) for all tumour cells as defined previously, with membrane reinforcement in a couple of cells (not shown) [31] . FISH analysis performed on the same paraffin block on serial sections demonstrated ALKrearranged adenocarcinomas (not shown). The other 82 tumours were negative for ALK immunostaining and for ALK rearrangement by using FISH analysis. Overall, ten tumours (12%) had an EGFR mutation (1 exon 18, 6 exon 19 and 3 exon 21 mutations) and 20 cases (23%) were KRAS mutated (18 codon 12 of exon 2 and 2 codon 13 of exon 2). The BRAF mutation was not detected. In addition, the five ALKrearranged tumours had EGFR, KRAS and BRAF wild-type status.
Positive ALK immunostaining was found in CTCs isolated in five patients, corresponding to the patients having ALKrearrangement in tumours ( Figure 1A1 and B1 and supplementary Figure S1 , available at Annals of Oncology online). The clinicopathological data of these five patients are detailed in Table 2 . The anti-ALK ICC using the 5A4 clone showed strong cytoplasmic staining (score 3+) of 100% of the CTCs with membrane reinforcements in most of the cells ( Figure 1A1 and B1 and supplementary Figure S1 , available at Annals of Oncology online). ALK FISH was informative in these five cases ( Figure 1A2 and B2 and supplementary Figure S1 , available at Annals of Oncology online). All CTCs had abnormal signal patterns with at least three signals observed per cell in each case, consistent with either gene amplification or aneusomy ( Figure 1A2 and B2 and supplementary Figure S1 , available at Annals of Oncology online). Moreover, FISH confirmed the presence of an ALK translocation, all cases having break apart of 5 0 and 3 0 probes and multiple signals per cells ( Figure 1A2 and B2 and supplementary Figure S1 , available at Annals of Oncology online). None of the five cases had loss of either part of the FISH probe. Finally, for these five patients, CTCs stained with MGG showed CTCs with malignant features, as described previously ( Figure 1A3 and B3 and supplementary Figure S1 , available at Annals of Oncology online) [22] . The positivity of ALK-ICC and ALK-FISH were controlled for each patient with circulating non-haematological cells with malignant features isolated using ISET at 7 and 15 days after the first detection.
No positive immunostaining with the anti-ALK antibody and no ALK rearrangement using FISH analysis were demonstrated in the 82 other selected patients with lung cancer showing CTCs with malignant features on MGG staining (Figure 1, C1-C3 ). ALK-rearranged H2228 cells diluted in blood samples, than filtered using the ISET method demonstrated strong positive ALK immunostaining and ALK translocation ( Figure 1D1-D3) .
The reproducibility of the results for the detection of ALK by ICC and FISH was tested on CTCs of 102 filters of blood samples from 34 patients who underwent blood sampling before surgery, and 7 and 15 days after surgery. Of the 34 patients included, 5 patients had ALK-positive tumour tissue and 29 patients had ALK-negative tumour tissue. Positive results were consistently obtained by ICC and FISH for CTC from the three different blood samples obtained from each of the five patients with ALK-positive tumours. Negative results for ALK were consistently obtained by ICC and FISH on CTC from the three different blood samples obtained from each of the 29 patients with ALK-negative tumours.
discussion
In this study, we have shown, using a dual ICC-FISH assay, that the ALK status can be detected non-invasively in CTCs characterised by a cytomorphological approach in a subset of patients with lung cancer. Moreover, our results demonstrated a strict correlation between the ALK status determined in CTCs and in the corresponding tumour tissue samples in a series of 87 patients with lung adenocarcinoma. Five of these patients had clinicopathological characteristics previously reported to be associated with ALK-gene rearrangement in the Western population and showed ALK-gene rearrangement both in CTCs and in the corresponding resected tumour samples [28] . Conversely, we never found CTCs with an ALKgene rearrangement in patients with a tumour without ALKgene rearrangement, as demonstrated by FISH. Recent studies focused on the relevance for the prognosis of ALK-positive lung cancer patients, independent of ALK-targeted therapy [33] [34] [35] . Some of these studies demonstrated that in patients not treated with pre-ALK inhibitors, ALK-positive patients had a shortest survival and were associated with a higher risk of metastasis [33, 35] . Moreover, ALK-positive patients were more resistant to EGFR tyrosine kinase inhibitor treatment than ALK-negative patients [33] . Conversely, a recent study demonstrated that patients with wild-type EGFR ALK-positive lung adenocarcinoma had a better outcome [34] . In the present work, the 5-year follow-up of the five EGFR wild-type ALK-positive patients showed no recurrence for the 2 stage II patients who underwent surgery, whereas the 3 stage IIIb/IV patients died within 6 months after the diagnosis. No adjuvant therapy, in particular no targeted therapy against ALK rearrangement, was administered in these patients.
The rationale for developing a non-invasive assay to detect ALK-gene rearrangement through CTCs isolation and characterisation is based on clinical considerations. Treatment with crizotinib has to be restricted to tumours with a proven ALK-gene rearrangement, which implies a systematic prescreening of tumour samples with the reliable technical approaches. However, tumour tissue from patients with lung cancer is not always available or in a sufficient amount to perform both the pathological examination and an increasing list of immuno/molecular analyses aimed at stratifying patients for the use of targeted therapies. At variance with free tumour DNA/RNA in plasma, which may be derived from apoptotic cells and lacks the tumour cell invasive properties, CTCs may represent a "liquid biopsy" and constitute the ideal target for non-invasive theranostic tests.
In this study, we have used the ISET approach to isolate CTCs, as we and others have shown that this method displays a high sensitivity for CTC isolation in NSCLC patients [15] [16] [17] . As previously pointed out, CTC isolation using ISET is dependent on cellular size and independent of any cellular marker. Thus, tumour cells expressing epithelial markers as well as those having lost epithelial antigens, due to EMT, are efficiently isolated using ISET [17, 21, 24, 25] . Moreover, ICC and molecular analyses, including FISH, can be developed in CTCs isolated and characterised using ISET [17, 18, 21, [23] [24] [25] . Interestingly, we demonstrated the reproducibility of the results for the detection of ALK by ICC and FISH on a subgroup of 34 patients tested before surgery and, 7 and 15 days after surgery, and including five ALK-positive patients for tumour tissue. Consistent results were obtained blindly in the three samples obtained from each patient. These results confirm the technical reproducibility of ICC and FISH analysis for ALK on filters and show the feasibility of a kinetic realtime follow-up of patients by CTC analysis.
Reliable assessment of ALK-gene rearrangement in lung tumour tissues is recognised as a diagnostic and technical challenge [31, 36] . The ALK status on tumour samples can be evaluated by using FISH, IHC and/or the reverse transcriptasepolymerase chain reaction (RT-PCR) [31, [35] [36] [37] [38] [39] . FISH is the diagnostic method used as an eligibility criterion in current clinical trials with crizotinib [38] . IHC with antibodies specific for the human ALK protein (antibody clone ALK1) is diagnostic for an ALK rearrangement in a subset of anaplastic large cell lymphomas, having such sensitivity and specificity that genetic tests are considered unnecessary [38] . In NSCLCs, the expression of the ALK protein from the rearranged ALK gene is lower. However, the development and use of new ALKspecific antibodies has provided very interesting results. In this study, we have used the anti-ALK antibody, clone 5A4, which has been recently shown to accurately type 20/20 NSCLC tumour tissues [36] . In the five ALK-rearranged cases, we noted that no more than 50% of tumour cells were ALK-FISH positive in the tumour, whereas 100% of these cells were ALK positive by IHC. However, IHC for ALK was heterogeneous in certain areas of the tumours, and some cells were only faintly stained (1+) whereas others were strongly stained (3+). Thus, as described in a recent study, a correlation between IHC and FISH for the ALK-gene rearrangement can be observed in only [40] , raising the issue of a better and more appropriate comparison between FISH-positive and "IHC 3+ only"-positive cells. As the preliminary data, the present study shows that ICC performed on CTCs may be a promising tool to detect ALK rearrangement as well as other genomic alterations, such as EGFR mutations. In this regard, some EGFR mutations can be demonstrated by IHC in a subset of lung adenocarcinomas using specific antibodies [31, 41] . We can speculate that such EGFR mutations could also be demonstrated using the ICC approach on CTCs in this subset of lung cancers. It is noteworthy that all CTCs detected in the present study were ALK-FISH positive and strongly positive by ICC using a specific antibody against ALK. We can, thus, speculate that CTCs harbouring this specific genomic alteration have facilitated migration and represent an aggressive set of tumour cells. ALK-gene rearrangement can also be detected by RT-PCR [30, 36] . RT-PCR is a challenging approach requiring high-quality RNA to afford amplification of multiple transcripts with variable sizes [36] . Finally, a quantitative real-time PCR approach has been recently developed to quantify ALK transcripts and obtained encouraging results [36] . In the present study, we did not try to look for ALK rearrangement using an RT-PCR approach, as we thought that the quantity and quality of the RNA we could potentially extract from CTCs isolated by ISET would not be sufficient for the test because the commercial buffer used for blood dilution before filtration contains formaldehyde. However, this strategy will be tested in the future in using a new ISET buffer developed to isolate fresh CTCs with unchanged sensitivity when compared with fixed CTCs. The use of non-invasive CTC-based tests could allow in the future implementation of real-time molecular theranostic follow-up of patients to identify potential new genomic alterations involved in resistance to targeted therapies [42] . In this regard, the emergence of acquired resistance to crizotinib is a new challenge in the clinical care of ALK-positive lung cancer patients [11, 43, 44] . In fact, new genomic alteration(s) may occur during crizotinib therapy and can make the initial targeted treatment inefficient. Thus, real-time monitoring could be developed in aiming to detect the potential additional genomic alterations through molecular tests for CTCs isolated by ISET and diagnostically characterised by a morphological approach.
In conclusion, our study has shown the feasibility of detection of ALK-gene rearrangement in CTCs isolated by ISET and characterised as CTCs with malignant features. We found consistent results by using the ICC and FISH molecular approaches and, importantly, we also found consistent results in CTCs when compared with tumour tissues in the 87 tested patients. Although studies of a larger cohort are needed to extensively validate these data, our results open the way for a CTC-based theranostic approach for evaluation of non-invasive ALK status pre-screening of patients with lung cancer. 
